B Cell News and Research

RSS

New oligomer shows promising anti-SARS-CoV-2 properties

Scientists from the University Of New Mexico have recently identified a new cationic oligomer that may help inactivate severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

20 Oct 2021

Scientists search for cause of mysterious covid-related inflammation in children

Like most other kids with covid, Dante and Michael DeMaino seemed to have no serious symptoms.

20 Oct 2021

Suggested mechanism of SARS-CoV-2 infection inhibition by Mitoxantrone

A group of researchers performed a drug repurposing screen on an FDA-approved anti-cancer drug named Mitoxantrone.

20 Oct 2021

UVA researchers identify an unknown trigger for epilepsy seizures

Researchers at the University of Virginia School of Medicine have uncovered how problems in cortical microcircuits in the brain can trigger epilepsy seizures.

20 Oct 2021

Long-term predictions of immunity after two doses of mRNA vaccine

Researchers from York University has investigated the long-term protection of two mRNA vaccines.

20 Oct 2021

BNT162b2 mRNA COVID-19 vaccine-induced antibodies wane over six month period

Researchers have been investigating the response of antibodies created against SARS-CoV-2 by the Pfizer-BioNTech six months after vaccination.

20 Oct 2021

Cat bacteria likely to form the basis for novel therapeutics against severe skin infections

Researchers at University of California San Diego School of Medicine used bacteria found on healthy cats to successfully treat a skin infection on mice. These bacteria may serve as the basis for new therapeutics against severe skin infections in humans, dogs and cats.

20 Oct 2021

New approach to predict the enzyme activity using AI

Without enzymes, an organism would not be able to survive. It is these biocatalysts that facilitate a whole range of chemical reactions, producing the building blocks of the cells. Enzymes are also used widely in biotechnology and in our households, where they are used in detergents, for example.

20 Oct 2021

An investigation of three SARS-CoV-2 mRNA doses in multiple sclerosis vaccine non-responders

A clinical study by a team of scientists from Norway aimed to assess the immunogenicity and safety of a third dose of COVID-19 mRNA vaccine in MS patients treated with anti-CD20 therapy or fingolimod. A preprint version of the study, which is yet to undergo peer review, is available on the medRxiv* server.

20 Oct 2021

Understanding how brain cells talk could help find new treatments for neurological, psychiatric conditions

Experts from the University of Nottingham have discovered that reversing the modification of molecular messages at synapses in the human brain, may contribute to reversible mental health conditions such as anxiety, and memory diseases such as dementia.

20 Oct 2021

Deep learning algorithm can accurately detect molecular pathways, key mutations in colorectal cancer

A new deep learning algorithm created by researchers from the University of Warwick can pick up the molecular pathways and development of key mutations causing colorectal cancer more accurately than existing methods, meaning patients could benefit from targeted therapies with quicker turnaround times and at a lower cost.

20 Oct 2021

Tau reduction impacts brain cells involved in creating abnormal activity

With the school year well on its way, we all recognize the importance of getting students energized. However, we also know that overstimulated children can wreak havoc on a classroom, leaving a teacher trying to regain control of their group. The situation is very similar in the brain, where cells must remain active - but in an orderly manner - to carry out their many important tasks.

20 Oct 2021

Microscopy-based high content platform for SARS-CoV-2 serological screening

A new study published on the medRxiv* preprint server used automated high content immunofluorescence microscopy (AHCIM) to assess the viability of such an approach to detect humoral immune responses against SARS-CoV-2 proteins.

20 Oct 2021

Collaborations and co-achievements of network of COST Actions on COVID-19

Addressing societal issues by enabling cross-disciplinary partnerships is an inherent part of a COST Actions' nature. But collaborations don't stop at the gate of these specific networks: multiple COST Actions have joined forces since the beginning of the pandemic to help advance research into COVID-19.

20 Oct 2021